Table 2 Associations between the G1790A polymorphism and cancer risk

Overall

25

1.85 (1.27-2.69 )

0

26

5.69 (3.87-8.37)

0

12

6.63 (4.49-9.79)

0

11

2.39 (1.53-3.75)

0

Overall for HWE ^c

22

1.82 (1.27-2.59)

0

10

7.01 (4.42-11.09)

0

10

7.75 (4.87-12.34)

0

10

3.4 (2–5.8)

0

cancer cite

Prostate cancer

3

1.41 (0.93-2.14)

0.1

1

3.24 (0.13-79.9)

0.47

1

3.34 (0.13-82.30)

0.46

1

1.98 (0.07-50.4)

0.67

Head and neck cancer

6

3.57 (0.98-12.99)

0.05

3

58 (1.75-1924.88)

0.02

3

101.38 (22.09-65.29)

0

3

12.53 (2.42-64.76)

0

Pancreatic cancer

2

2.5 ( 0.93-6.72)

0.06

1

18.8 (0.96-371.55)

0.05

1

18.3 (0.93-360.19)

0.05

1

29.4 (1.12-772.37)

0.04

Lung cancer

3

2.14 ( 1.56-2.95)

0

2

4.5 (2.3-8.81)

0

2

5.42 (2.74-10.7)

0

2

3.02 (1.48-6.16)

0

Renal cell carcinoma

3

0.94 ( 0.16-5.29)

0.95

2

2.69 (1.20-6.03)

0.01

2

3.71 (1.72-7.99)

0.46

1

0.81 (0.33-2)

0.65

Other cancer

5

2.11 ( 1.03-4.32)

0.45

1

0.35 (0.01-8.80)

0.53

1

0.35 (0.01-8.8)

0.52

1

0.36 (0.01-9.68)

0.54

Breast cancer

3

0.63 ( 0.19-2.08)

0

2

1.44 (0.34-6.08)

0.62

2

1.43 (0.37-5.44)

0.59

2

1.45 (0.34-6.17)

0.61

Subgroup by ethnicity

Asian

13

1.75 (1.3-2.37)

0

7

3.37 (1.94-5.86)

0

7

3.82 (2.19-6.66)

0

7

2.41 (1.31-4.43)

0

Caucasian

9

1.12 (0.41-3.03)

0.81

4

3.74 (1.85-7.54)

0

4

5.05 (2.53-10.07)

0

3

2.66 (0.33-21.23)

0.35

control source

PB

22

1.95 (1.33-2.85)

0

11

5.9 (4.0-8.8)

0

11

7.2 (4.79-10.82)

0

11

2.39 (1.53-3.75)

0

HB

3

0.39 (0.01-9.90)

0.56

1

0.88 (0.04-16.82) ^c

0.93

1

0.44 (0.02-8.53)

0.59

0

No statistics

Gender

Female

5

0.92 (0.46-1.84)

0.82

3

1.11 (0.34-3.66)

0.85

3

1.13 (0.34-3.7)

0.83

3

1.13 (0.31-4.02)

0.84

Male

3

1.41 (0.93-2.14)

0.1

1

3.24 (0.13-79.9)

0.47

1

3.34 (0.13-82.3)

0.46

1

1.98 (0.07-50.4)

0.67